Difference between revisions of "Non-small cell lung cancer, HER2-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.clinicaltrials.gov/ct2/show/[https://clinicaltrials.gov/ct2/show/" to "https://www.clinicaltrials.gov/ct2/show/") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
Line 30: | Line 30: | ||
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https://www.clinicaltrials.gov/ | + | |[https://www.clinicaltrials.gov/study/NCT04644237 Awaiting publication (DESTINY-Lung02)] |
|2021-ongoing | |2021-ongoing | ||
|style="background-color:#91cf61"|Phase 2 (RT) | |style="background-color:#91cf61"|Phase 2 (RT) | ||
Line 55: | Line 55: | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
|- | |- | ||
− | |[https://www.clinicaltrials.gov/ | + | |[https://www.clinicaltrials.gov/study/NCT04644237 Awaiting publication (DESTINY-Lung02)] |
|2021-ongoing | |2021-ongoing | ||
|style="background-color:#91cf61"|Phase 2 | |style="background-color:#91cf61"|Phase 2 | ||
Line 70: | Line 70: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9066448/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] [https://clinicaltrials.gov/ | + | #'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9066448/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] [https://clinicaltrials.gov/study/NCT03505710 Clinical Trial Registry] |
− | #'''DESTINY-Lung02:''' [https://clinicaltrials.gov/ | + | #'''DESTINY-Lung02:''' [https://clinicaltrials.gov/study/NCT04644237 Clinical Trial Registry] |
[[Category:Non-small cell lung cancer regimens]] | [[Category:Non-small cell lung cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Non-small cell lung cancers]] | [[Category:Non-small cell lung cancers]] |
Revision as of 01:33, 25 June 2023
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
4 variants on this page
|
Guidelines
ASCO
- 2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
ESMO
- 2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Metastatic disease, all lines of therapy
Trastuzumab deruxtecan monotherapy
Regimen variant #1, 5.4 mg/kg
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 (RT) |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 5.4 mg/kg IV once on day 1
21-day cycles
Regimen variant #2, 6.4 mg/kg
Study | Dates of enrollment | Evidence |
---|---|---|
Li et al. 2021 (DESTINY-Lung01) | 2018-2020 | Phase 2 |
Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 6.4 mg/kg IV once on day 1
21-day cycles
References
- DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. link to original article contains dosing details in manuscript link to PMC article PubMed Clinical Trial Registry
- DESTINY-Lung02: Clinical Trial Registry